EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells

These findings show that combining an epigenetic therapy with a noncanonical WNT signaling pathway inhibitor has the potential to eradicate ovarian cancer stem cells and to prevent ovarian cancer recurrence. The majority of women diagnosed with epithelial ovarian cancer eventually develop recurrence, which rapidly evolves into chemoresistant disease. Persistence of ovarian cancer stem cells (OCSC) at the end of therapy may be responsible for emergence of resistant tumors. In this study, we demonstrate that in OCSC, the tumor suppressor disabled homolog 2–interacting protein (DAB2IP) is silenced by EZH2-mediated H3K27 trimethylation of the DAB2IP promoter. CRISPR/Cas9-mediated deletion of DAB2IP in epithelial ovarian cancer cell lines upregulated expression of stemness-related genes and induced conversion of non-CSC to CSC, while enforced expression of DAB2IP suppressed CSC properties. Transcriptomic analysis showed that overexpression of DAB2IP in ovarian cancer significantly altered stemness-associated genes and bioinformatic analysis revealed WNT signaling as a dominant pathway mediating the CSC inhibitory effect of DAB2IP. Specifically, DAB2IP inhibited WNT signaling via downregulation of WNT5B, an important stemness inducer. Reverse phase protein array further demonstrated activation of noncanonical WNT signaling via C-JUN as a downstream target of WNT5B, which was blocked by inhibiting RAC1, a prominent regulator of C-JUN activation. Coadministration of EZH2 inhibitor GSK126 and RAC1 inhibitor NSC23766 suppressed OCSC survival in vitro and inhibited tumor growth and increased platinum sensitivity in vivo. Overall, these data establish that DAB2IP suppresses the cancer stem cell phenotype via inhibition of WNT5B-induced activation of C-JUN and can be epigenetically silenced by EZH2 in OCSC. Targeting the EZH2/DAB2IP/C-JUN axis therefore presents a promising strategy to prevent ovarian cancer recurrence and has potential for clinical translation. Significance: These findings show that combining an epigenetic therapy with a noncanonical WNT signaling pathway inhibitor has the potential to eradicate ovarian cancer stem cells and to prevent ovarian cancer recurrence.

[1]  K. Nephew,et al.  Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting , 2019, Cancers.

[2]  Yan Wang,et al.  Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop , 2019, Journal of cellular biochemistry.

[3]  D. Matei,et al.  IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. , 2018, JCI insight.

[4]  Min Huang,et al.  Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors , 2018, Cell.

[5]  A. Jemal,et al.  Ovarian cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[6]  M. Stack,et al.  Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion , 2018, Molecular Cancer Research.

[7]  Fang Fang,et al.  Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs. , 2018, Cancer research.

[8]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[9]  J. Chang,et al.  Tumour cell-derived WNT5B modulates in vitro lymphangiogenesis via induction of partial endothelial-mesenchymal transition of lymphatic endothelial cells , 2017, Oncogene.

[10]  J. Borg,et al.  Wnt/Planar Cell Polarity Signaling: New Opportunities for Cancer Treatment. , 2017, Trends in cancer.

[11]  L. Collavin,et al.  Block one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer , 2016, Cell Death and Differentiation.

[12]  K. Nephew,et al.  Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease , 2016, Oncotarget.

[13]  J. Gong,et al.  DAB2IP in cancer , 2015, Oncotarget.

[14]  Xiao-lan Li,et al.  Absence of DAB2IP promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer , 2015, Scientific Reports.

[15]  Tuan Zea Tan,et al.  CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype , 2015, Oncotarget.

[16]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[17]  M. Gleave,et al.  Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[18]  Tudor I. Oprea,et al.  A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients , 2015, Clinical Cancer Research.

[19]  Leonid Peshkin,et al.  A Noncanonical Frizzled2 Pathway Regulates Epithelial-Mesenchymal Transition and Metastasis , 2014, Cell.

[20]  H. B. Pearson,et al.  Dissecting the role of polarity regulators in cancer through the use of mouse models. , 2014, Experimental cell research.

[21]  D. Matei,et al.  Epigenetic targeting of ovarian cancer stem cells. , 2014, Cancer research.

[22]  R. Kittler,et al.  DAB2IP regulates cancer stem cell phenotypes through modulating stem cell factor receptor and ZEB1 , 2014, Oncogene.

[23]  R. Weinberg,et al.  Tackling the cancer stem cells — what challenges do they pose? , 2014, Nature Reviews Drug Discovery.

[24]  T. Tan,et al.  FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway , 2014, Cell Death and Disease.

[25]  J. Li,et al.  Wnt modulates MCL1 to control cell survival in triple negative breast cancer , 2014, BMC Cancer.

[26]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[27]  M. Kool,et al.  EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival , 2012, Clinical Cancer Research.

[28]  M. Banerjee,et al.  Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells , 2012, International journal of cancer.

[29]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[30]  K. Griffith,et al.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. , 2011, Cancer research.

[31]  W. Woodward,et al.  EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. , 2011, Cancer cell.

[32]  Robert Brown,et al.  Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2 , 2011, Molecular Cancer Therapeutics.

[33]  M. Hung,et al.  CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells , 2011, Nature Cell Biology.

[34]  R. Bast,et al.  Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer , 2010, Molecular Cancer Therapeutics.

[35]  R. Zeillinger,et al.  ABC transporter gene expression in benign and malignant ovarian tissue. , 2010, Gynecologic oncology.

[36]  Ji-Eun Lee,et al.  Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis , 2010, Proceedings of the National Academy of Sciences.

[37]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[38]  J. Fletcher,et al.  ABC transporters in cancer: more than just drug efflux pumps , 2010, Nature Reviews Cancer.

[39]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[40]  S. Richon,et al.  In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy , 2010, BMC Cancer.

[41]  D. Roberts,et al.  CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer , 2009, Stem cells.

[42]  J. Marks,et al.  Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells , 2009, Oncogene.

[43]  Z. Xuan,et al.  Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma , 2008, Cell.

[44]  Curt Balch,et al.  Identification and characterization of ovarian cancer-initiating cells from primary human tumors. , 2008, Cancer research.

[45]  Valeri Vasioukhin,et al.  Cell polarity and cancer – cell and tissue polarity as a non-canonical tumor suppressor , 2008, Journal of Cell Science.

[46]  M. Katoh,et al.  WNT Signaling Pathway and Stem Cell Signaling Network , 2007, Clinical Cancer Research.

[47]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[48]  S. Bapat,et al.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. , 2005, Cancer research.

[49]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[50]  P. Crespo,et al.  The small GTP-binding proteins Rac1 and Cdc42regulate the activity of the JNK/SAPK signaling pathway , 1995, Cell.